JP2018532715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532715A5 JP2018532715A5 JP2018512876A JP2018512876A JP2018532715A5 JP 2018532715 A5 JP2018532715 A5 JP 2018532715A5 JP 2018512876 A JP2018512876 A JP 2018512876A JP 2018512876 A JP2018512876 A JP 2018512876A JP 2018532715 A5 JP2018532715 A5 JP 2018532715A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- region
- seq
- acid sequence
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131502A JP2021181479A (ja) | 2015-09-11 | 2021-08-12 | 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562217320P | 2015-09-11 | 2015-09-11 | |
| US62/217,320 | 2015-09-11 | ||
| PCT/EP2016/071336 WO2017042352A1 (en) | 2015-09-11 | 2016-09-09 | Dosing regimens for anti-tf-antibody drug-conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131502A Division JP2021181479A (ja) | 2015-09-11 | 2021-08-12 | 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532715A JP2018532715A (ja) | 2018-11-08 |
| JP2018532715A5 true JP2018532715A5 (enExample) | 2019-10-17 |
| JP6978409B2 JP6978409B2 (ja) | 2021-12-08 |
Family
ID=56926176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512876A Expired - Fee Related JP6978409B2 (ja) | 2015-09-11 | 2016-09-09 | 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン |
| JP2021131502A Pending JP2021181479A (ja) | 2015-09-11 | 2021-08-12 | 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131502A Pending JP2021181479A (ja) | 2015-09-11 | 2021-08-12 | 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190030178A1 (enExample) |
| EP (2) | EP3919081A1 (enExample) |
| JP (2) | JP6978409B2 (enExample) |
| CY (1) | CY1124532T1 (enExample) |
| DK (1) | DK3347054T3 (enExample) |
| ES (1) | ES2877527T3 (enExample) |
| HU (1) | HUE055109T2 (enExample) |
| PL (1) | PL3347054T3 (enExample) |
| PT (1) | PT3347054T (enExample) |
| SI (1) | SI3347054T1 (enExample) |
| WO (1) | WO2017042352A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3071237T1 (sl) | 2013-11-21 | 2024-11-29 | Genmab A/S | Liofilizirana formulacija konjugata protitelo-zdravilo |
| BR112020008593A2 (pt) * | 2017-11-02 | 2020-10-20 | Genmab A/S | método de tratamento de câncer cervical em um indivíduo |
| KR20240134250A (ko) | 2018-01-04 | 2024-09-06 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
| SG11202007865VA (en) * | 2018-03-07 | 2020-09-29 | Genmab As | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |
| TWI841554B (zh) * | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| JP7460608B2 (ja) * | 2018-05-07 | 2024-04-02 | ジェンマブ エー／エス | 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法 |
| EA202190102A1 (ru) * | 2018-08-16 | 2021-07-29 | Генмаб А/С | Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака |
| TWI844571B (zh) * | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| JP7406784B2 (ja) * | 2019-04-17 | 2023-12-28 | 国立大学法人金沢大学 | 卵巣癌の検出方法 |
| WO2021090272A1 (en) * | 2019-11-07 | 2021-05-14 | Genmab A/S | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| TW202131954A (zh) * | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| EP2326350B1 (en) * | 2008-09-08 | 2013-09-04 | Psma Development Company, L.L.C. | Compounds for killing psma-expressing, taxane-resistant cancer cells |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| WO2010081004A1 (en) | 2009-01-09 | 2010-07-15 | Seattle Genetics, Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー／エス | 組織因子に対するヒト抗体薬物結合体 |
| SI3071237T1 (sl) | 2013-11-21 | 2024-11-29 | Genmab A/S | Liofilizirana formulacija konjugata protitelo-zdravilo |
-
2016
- 2016-09-09 HU HUE16765958A patent/HUE055109T2/hu unknown
- 2016-09-09 SI SI201631250T patent/SI3347054T1/sl unknown
- 2016-09-09 PL PL16765958T patent/PL3347054T3/pl unknown
- 2016-09-09 EP EP21171350.8A patent/EP3919081A1/en not_active Withdrawn
- 2016-09-09 DK DK16765958.0T patent/DK3347054T3/da active
- 2016-09-09 ES ES16765958T patent/ES2877527T3/es active Active
- 2016-09-09 EP EP16765958.0A patent/EP3347054B1/en active Active
- 2016-09-09 JP JP2018512876A patent/JP6978409B2/ja not_active Expired - Fee Related
- 2016-09-09 WO PCT/EP2016/071336 patent/WO2017042352A1/en not_active Ceased
- 2016-09-09 PT PT167659580T patent/PT3347054T/pt unknown
- 2016-09-09 US US15/758,520 patent/US20190030178A1/en not_active Abandoned
-
2021
- 2021-07-26 CY CY20211100669T patent/CY1124532T1/el unknown
- 2021-08-12 JP JP2021131502A patent/JP2021181479A/ja active Pending
- 2021-12-10 US US17/548,436 patent/US20220265844A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240415917A1 (en) | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates | |
| JP6382221B2 (ja) | プロラクチン受容体結合タンパク質およびそれらの使用 | |
| ES2824120T3 (es) | Procedimientos de tratamiento del cáncer usando inhibidores de b-raf e inhibidores de los puntos de control inmunitario | |
| JP2023535443A5 (enExample) | ||
| US20110027273A1 (en) | Immunotherapy of autoimmune disorders | |
| JP2015528818A5 (enExample) | ||
| PT2576618T (pt) | Anticorpos contra gdf8 humano | |
| TW201024315A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide | |
| JP2019524713A5 (enExample) | ||
| JP2021501776A5 (enExample) | ||
| CN115957321A (zh) | 一种抗her2抗体在制备治疗癌症的药物中的用途 | |
| US8758758B1 (en) | Post-relapse treatment of CD30 expressing lymphomas | |
| JP2005529152A5 (enExample) | ||
| JP2025508389A5 (enExample) | ||
| KR20230129446A (ko) | 암에 대한 for46과의 병용 요법 | |
| CA3004348C (en) | Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors | |
| CA3187136A1 (en) | Methods of treating thyroid eye disease and graves' orbitopahy using interleukin-17 (il-17) antagonists |